ArticleClinical oral investigations2026
A preliminary antimicrobial investigation of lactobacillus bulgaricus probiotic supernatants as an intracanal medication against mature E. faecalis biofilm in an ex-vivo dentin blocks model.
Article in Clinical oral investigations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo provide a preliminary assessment of the antimicrobial potential of Lactobacillus bulgaricus probiotic against mature Enterococcus faecalis biofilm in dentin model under ex-vivo conditions using confocal laser scanning microscopy (CLSM).
methodsLactobacillus bulgaricus and Lactobacillus acidophilus probiotic strains were grown, centrifuged, filtered by syringe filter size 0.45 microns to acquire cell free supernatants (CFS). Lyophilized CFS of each probiotic strain was individually mixed with Poloxamer gel using cold technique to prepare probiotic supernatants (PS) gel. Dentin blocks from cervical root portions were standardized at similar dimensions, infected with E. faecalis for 21 days to generate a mature biofilm. At the end of incubation, infected dentin blocks were randomly assigned to five groups (n = 10) based on the medication as follows: positive control (PC), calcium hydroxide (CH), Lactobacillus acidophilus PS gel (LA), Lactobacillus bulgaricus PS gel (LB), Lactobacillus combination PS gel (LC) combining LA and LB at a 1:1 ratio. All dentin blocks were medicated and incubated for 7 days under anaerobic conditions. Then, dentin blocks were examined with CLSM at 40X magnification; three-dimensional imaging in Z-stack mode was processed, and the dead E. faecalis% was quantitatively assessed using bioImage_L v21 software and total biovolume was calculated. Dead E. faecalis% were compared across groups using a one-way ANOVA test followed by Tukey's post hoc test. Biovolume data were compared using the Kruskal-Wallis test followed by Dunn's post hoc test with p-value adjustment using Holm's method. The significance level was set at p < 0.05 for all tests. Statistical analysis was performed using R version 4.6.0 for Windows.
resultsLB was linked to the highest percentage of dead E. faecalis% (p < 0.05), followed by LC, LA, CH, and the PC. Significant differences in dead E. faecalis% were observed between all groups (p < 0.05) except for CH and the PC groups. There was no significant difference in total biovolume among all groups.
conclusionThe Initial assessment of LB showed a promising antimicrobial action in dentin model that exceeded LA and CH. As biofilm biovolume was unaffected, LB appears to reduce bacterial viability rather than remove biofilm mass, warranting further validation in polymicrobial and intact canal models. CLINICAL SIGNIFICANCE: Probiotics may be of clinical relevance due to their antimicrobial action against E. faecalis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.